NG Bio is a therapeutic venture firm established in 2020 and based in London, United Kingdom. The company focuses on developing innovative solutions to improve outcomes for patients suffering from autoimmune and chronic inflammatory diseases. By investing in healthcare and biotechnology companies, NG Bio aims to advance therapies that address these significant health challenges. Through its strategic investments, the firm seeks to foster advancements in medical science that can lead to better treatment options for affected individuals.
Mesenbio is a preclinical biopharmaceutical company located at the University of York, specializing in cell-derived therapies. It employs a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which enhances the development of treatments by addressing common challenges in extracellular vesicle therapy. The company is focused on creating innovative treatments for conditions such as arthritis, utilizing engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio aims to improve access to effective therapies for musculoskeletal diseases, thereby contributing to advancements in medical treatment.
Bastion Therapeutics
Venture Round in 2023
Bastion Therapeutics is a preclinical stage biotechnology startup focused on developing innovative anti-inflammatory cell therapies. The company utilizes proprietary platform technology to enhance regulatory T cells (Tregs) within the immune system. By targeting neuroinflammation in the central nervous system, Bastion's therapies aim to protect neurons and improve synaptic connectivity. This approach seeks to help patients maintain cognitive function and prevent its decline, addressing significant challenges in neurodegenerative conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.